ENCOURAGING DATA FROM A PHASE I STUDY OF THE FIRST ORAL PARP INHIBITOR OLAPARIB IN JAPANESE PATIENTS WITH SOLID TUMOURS

被引：0
|
作者：
Yamamoto, N. [1 ]
Nokihara, H. [1 ]
Yamada, Y. [1 ]
Goto, Y. [1 ]
Tanioka, M. [1 ]
Shibata, T. [1 ]
Yamada, K. [1 ]
Asahina, H. [1 ]
Tamura, T. [1 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：176 / 176
页数：1
相关论文
共 50 条
  • [1] A pharmacodynamic (PD) evaluation of the PARP inhibitor olaparib (AZD2281) in a first-in-human Phase I trial of patients with advanced solid tumours
    Lau, Alan
    McCormack, Peter
    Mangena, Ramu
    Gaboriau, David
    Knights, Charlotte
    Unwin, Louise
    Wu, Peijun
    Cranston, Aaron
    Boss, David
    Mergui-Roelvink, Marja
    Fong, Peter
    Yap, Timothy
    Ashworth, Alan
    Kaye, Stan
    Schellens, Jan
    de Bono, Johann
    Carmichael, James
    Tutt, Andrew
    Swaisland, Helen
    O'Connor, Mark
    CANCER RESEARCH, 2009, 69
  • [2] First in Children Phase I Clinical Study of Oral Olaparib in Pediatric Patients with Refractory Solid Tumors
    Takagi, M.
    Ogawa, C.
    Iehara, T.
    Aoki-Nogami, Y.
    Isibashi, E.
    Imai, M.
    Kimura, T.
    Nagata, M.
    Yasuhara, M.
    Masutani, M.
    Yoshimura, K.
    Tomizawa, D.
    Ogawa, A.
    Yonemori, K.
    Kihara, T.
    Nobori, K.
    Hasebe, K.
    Mizutani, S.
    Morio, T.
    Hosoi, H.
    Koike, R.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S85 - S86
  • [3] PHASE I STUDY OF RESMINOSTAT, AN ORAL HDAC INHIBITOR, IN JAPANESE PATIENTS WITH SOLID TUMORS
    Kitazono, Satoru
    Fujiwara, Yutaka
    Nakamichi, Shinji
    Mizugaki, Hidenori
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2014, 25
  • [4] First in Children Phase I Clinical Study of Oral Olaparib in Pediatric Patients with Refractory Solid Tumors
    Takagi, Masatoshi
    Ogawa, Chitose
    Iehara, Tomoko
    Nogami, Yuki
    Tomizawa, Daisuke
    Ogawa, Atsushi
    Takita, Junko
    Mizutani, Shuki
    Morio, Tomohiro
    Hosoi, Hajime
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [5] Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
    G Del Conte
    C Sessa
    R von Moos
    L Viganò
    T Digena
    A Locatelli
    E Gallerani
    A Fasolo
    A Tessari
    R Cathomas
    L Gianni
    British Journal of Cancer, 2014, 111 : 651 - 659
  • [6] Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
    Del Conte, G.
    Sessa, C.
    von Moos, R.
    Vigano, L.
    Digena, T.
    Locatelli, A.
    Gallerani, E.
    Fasolo, A.
    Tessari, A.
    Cathomas, R.
    Gianni, L.
    BRITISH JOURNAL OF CANCER, 2014, 111 (04) : 651 - 659
  • [7] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumours
    Okamoto, N.
    Hatake, K.
    Yamamoto, N.
    Takahashi, S.
    Boku, N.
    Kobayashi, K.
    Sakatani, K.
    Hirashima, T.
    Matsui, K.
    EJC SUPPLEMENTS, 2008, 6 (12): : 133 - 133
  • [8] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
  • [9] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Seki, Yoshitaka
    Yamamoto, Noboru
    Tamura, Yosuke
    Goto, Yasushi
    Shibata, Takashi
    Tanioka, Maki
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shimamoto, Takashi
    Noguchi, Kazuo
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1099 - 1105
  • [10] A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.
    Molife, L. R.
    Forster, M. D.
    Krebs, M.
    Pwint, T.
    Middleton, M. R.
    Kaye, S. B.
    McCormack, P.
    Swaisland, H.
    Carmichael, J.
    Ranson, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345